Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK

Anthony Cleare; Jess Kerr Gaffney; Kimberley Goldsmith; Zohra Zenasni; Nahel Yaziji; Huajie Jin; Alessandro Colasanti; John Geddes; R. Hamish McAllister-Williams; Allan Young; Alvaro Barrera; Lindsey Marwood; Rachael Taylor; Helena Tee

Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK

Anthony Cleare, Jess Kerr Gaffney, Kimberley Goldsmith, Zohra Zenasni, Nahel Yaziji, Huajie Jin, Alessandro Colasanti, John Geddes, R. Hamish McAllister-Williams, Allan Young, Alvaro Barrera, Lindsey Marwood, Rachael Taylor, Helena Tee

Research output: Contribution to journal › Article › peer-review

4 Downloads (Pure)

Original language	English
Pages (from-to)	278-288
Journal	The Lancet Psychiatry
Volume	12
Publication status	Published - 19 Mar 2025

Access to Document

ManuscriptFinal published version, 1.53 MB

Cite this

Cleare, A., Kerr Gaffney, J., Goldsmith, K., Zenasni, Z., Yaziji, N., Jin, H., Colasanti, A., Geddes, J., McAllister-Williams, R. H., Young, A., Barrera, A., Marwood, L., Taylor, R., & Tee, H. (2025). Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK. The Lancet Psychiatry, 12, 278-288.

@article{836c956446cf42ef982e7fdb2945bc87,

title = "Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK",

author = "Anthony Cleare and {Kerr Gaffney}, Jess and Kimberley Goldsmith and Zohra Zenasni and Nahel Yaziji and Huajie Jin and Alessandro Colasanti and John Geddes and McAllister-Williams, {R. Hamish} and Allan Young and Alvaro Barrera and Lindsey Marwood and Rachael Taylor and Helena Tee",

year = "2025",

month = mar,

day = "19",

language = "English",

volume = "12",

pages = "278--288",

journal = "The Lancet Psychiatry",

issn = "2215-0366",

publisher = "Elsevier",

}

Cleare, A , Kerr Gaffney, J , Goldsmith, K , Zenasni, Z , Yaziji, N , Jin, H , Colasanti, A, Geddes, J, McAllister-Williams, RH, Young, A, Barrera, A, Marwood, L , Taylor, R & Tee, H 2025, 'Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK', The Lancet Psychiatry, vol. 12, pp. 278-288.

Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK. / Cleare, Anthony ; Kerr Gaffney, Jess ; Goldsmith, Kimberley et al.
In: The Lancet Psychiatry, Vol. 12, 19.03.2025, p. 278-288.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK

AU - Cleare, Anthony

AU - Kerr Gaffney, Jess

AU - Goldsmith, Kimberley

AU - Zenasni, Zohra

AU - Yaziji, Nahel

AU - Jin, Huajie

AU - Colasanti, Alessandro

AU - Geddes, John

AU - McAllister-Williams, R. Hamish

AU - Young, Allan

AU - Barrera, Alvaro

AU - Marwood, Lindsey

AU - Taylor, Rachael

AU - Tee, Helena

PY - 2025/3/19

Y1 - 2025/3/19

M3 - Article

SN - 2215-0366

VL - 12

SP - 278

EP - 288

JO - The Lancet Psychiatry

JF - The Lancet Psychiatry

ER -